Nikolas E. J. Schmitz

Nikolas E. J. Schmitz

Auto-generated profile, based on publicly available information

Nikolas E. J. Schmitz

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
NSNikolas E. J. Schmitz
Nikolas E. J. Schmitz
CRCristina Richie
Cristina Richie
RSRaghavendra Selvan
Raghavendra Selvan
LLLoïc Lannelongue
Loïc Lannelongue
ASAriel Dora Stern
Ariel Dora Stern
PBPeter Boor
Peter Boor

14 July 2026 in EBioMedicine
Verified
Journal Article
Open access
DHDavid L Hölscher
David L Hölscher
NSNikolas E J Schmitz
Nikolas E J Schmitz
LNLeon Niggemeier
Leon Niggemeier
PPPourya Pilva
Pourya Pilva
MSMartin Strauch
Martin Strauch
AGAI4IgAN study group
AI4IgAN study group
IgA nephropathy (IgAN) has diverse clinical presentations and responses to treatment. For systemic corticosteroids in particular, randomised controlled trials have reported conflicting effects, highlighting the need for individualised treatment strategies. In this retrospective cohort study, we derived and validated a causal machine learning (ML) framework to estimate individualised corticosteroid treatment effects in IgAN. Eight international cohorts, including the VALIGA, CureGN, and NURTuRE-CKD repositories, comprising 1022 patients, were analysed (derivation, n = 464; validation, n = 558). We integrated baseline clinical data, histopathological classification scores (MEST-C), and deep learning-based histomorphological biomarkers (pathomics) from digitised kidney biopsies. The framework estimated the effect of systemic corticosteroids on the composite endpoint of a ≥50% decline in estimated glomerular filtration rate or kidney failure within five years of biopsy. Across the overall study population, systemic corticosteroid therapy was not associated with a significant improvement in the composite outcome (p = 0·27). However, the causal ML framework revealed substantial treatment heterogeneity, identifying patients with high predicted benefit who achieved longer progression-free survival with corticosteroids (0·43 years, 95% CI 0·18-0·73, p < 0·01), while no benefit was observed in those with low predicted benefit (-0·005 years, 95% CI -0·3 to 0·22, p > 0·05). An individualised framework-guided treatment assignment was estimated to reduce systemic corticosteroid use by 60·7%. Pathomics facilitated the identification of interstitial inflammation and tubulitis as key features of corticosteroid response. This study demonstrates that a causal ML framework integrating clinical, histopathological, and pathomics predictors can individualise treatment assignments for systemic corticosteroids in IgAN. This approach provides a blueprint for precision therapy in IgAN, supporting AI-enhanced clinical decision-making in the era of emerging targeted treatments. German Research Foundation; European Research Council; German Federal Ministry of Education and Research; German Innovation Fund of the Federal Joint Committee; Clinician Scientist Program of the Faculty of Medicine RWTH Aachen University.

9 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DHDavid L Hoelscher
David L Hoelscher
NSNikolas Ej Schmitz
Nikolas Ej Schmitz
LNLeon Niggemeier
Leon Niggemeier
PPPourya Pilva
Pourya Pilva
MSMartin Strauch
Martin Strauch
DHD. L. Hölscher
D. L. Hölscher
IgA nephropathy (IgAN) is a leading cause of kidney failure with diverse clinical presentations and treatment responses, particularly to corticosteroids, with conflicting evidence. Due to potentially severe side effects and heterogenous responses more individualized approaches are needed. We developed a causal machine learning framework for predicting individualized treatment effects of corticosteroids in IgAN by integrating clinical variables, histopathological scores, and deep learning-based biomarkers from digitized kidney biopsies (pathomics) of 1,022 patients from eight retrospective international cohorts. At the cohort-level, corticosteroids showed no significant effect on five-year kidney survival. However, the framework identified subpopulations with and without significant treatment benefit, improving progression-free kidney survival and also reducing overtreatment in low-benefit patients. Pathomics highlighted tubulointerstitial inflammation and glomerular tuft deformation as predictors of corticosteroid response. Our framework offers a blueprint for precision therapy in IgAN, supporting clinical decision-making in the era of emerging targeted treatments.